Precision immunotherapy with CAR-T cells in pediatric B-cell acute lymphoblastic leukemia: advances and unanswered challenges

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a groundbreaking treatment for pediatric B-cell acute lymphoblastic leukemia (B-ALL), especially for patients with relapsed or refractory disease. CD19-targeted CAR T cells, such as tisagenlecleucel, have demonstrated high rates of comple...

Cijeli opis

Bibliografski detalji

Glavni autori:	Fu Li, Libo Zheng
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-01-01
Serija:	Frontiers in Oncology
Teme:	CAR-T therapy cytokine release syndrome immune effector cell-associated neurotoxicity syndrome pediatric B-ALL tisagenlecleucel
Online pristup:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1691189/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!